The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Open accessAbstract
BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study. METHODS: We conducted an international, phase 2, pivotal study of centrally manufactured tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation. The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee. RESULTS: A total of 93 patients received an infusion and were included in the evaluation of efficacy. The median time from infusion to data cutoff was 14 months (range, 0.1 to 26). The best overall response rate was 52% (95% confidence interval, 41 to 62); 40% of the patients had complete responses, and 12% had partial responses. Response rates were consistent across prognostic subgroups. At 12 months after the initial response, the rate of relapse-free survival was estimated to be 65% (79% among patients with a complete response). The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome (22%), neurologic events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile neutropenia (14%). Three patients died from disease progression within 30 days after infusion. No deaths were attributed to tisagenlecleucel, cytokine release syndrome, or cerebral edema. No differences between response groups in tumor expression of CD19 or immune checkpoint-related proteins were found. CONCLUSIONS: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. (Funded by Novartis; JULIET ClinicalTrials.gov number, NCT02445248 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
In the citing paper
“However, despite high initial response rates, complete and long-term remission is only achieved in up to 40% of patients13–16.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [16]
In the citing paper
“Efficacy results seem similar in patients with LBCL treated with CD19 CAR T cells costimulated by 4-1BB instead of CD28, with or without fixing the ratio of CD4:CD8 cells.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Self-citationOutcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Neste, É. V. D., Kuruvilla, J. G., Westin, J. R., Link, B. K., Hay, A. E., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,755
Self-citationPorter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Gisselbrecht, C., Glaß, B., Mounier, N., Gill, D. S., Linch, D. C., Trněný, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,639
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 2017;130:577-577. abstract.
- Maude SL, Grupp SA, Pulsipher MA, et al. Analysis of safety data from 2 multicenter trials of CTL019 in pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Haematologica 2017;102:197-198.
Cited by
Sorted by citations
Items 501–600 of 1,010
Levine, J. E., Grupp, S. A., Pulsipher, M. A., Dietz, A. C., Rives, S., Myers, G. D., August, K. J., Verneris, M. R., Buechner, J., Laetsch, T. W., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002287 · Cited by 68
Sidana, S., Dueck, A. C., Thanarajasingam, G., Griffin, J. M., Thompson, C. A., Durani, U., Burtis, M., Warsame, R. M., Paludo, J., Gertz, M. A., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.05.004 · Cited by 66
Li, Y., Ming, Y., Fu, R., Li, C., Wu, Y., Jiang, T., Li, Z., Ni, R., Li, L., Su, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.950923 · Cited by 75
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Qu, C., Zhang, H., Cao, H., Tang, L., Mo, H., Liu, F., Zhang, L., Yi, Z., Long, L., Yan, L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01669-8 · Cited by 68
Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
Vodička, P., Klener, P., & Trněný, M. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s326632 · Cited by 70
Fischer, L., Grieb, N., Born, P., Weiss, R., Seiffert, S., Boldt, A., Fricke, S., Franz, P., Heyn, S., Kubasch, A. S., et al. (2024) · Leukemia · doi:10.1038/s41375-023-02129-y · Cited by 67
Kim, J., Cho, J., Lee, M. H., Yoon, S. E., Kim, W. S., & Kim, S. J. (2024) · Blood · doi:10.1182/blood.2023023419 · Cited by 66
Advances in biology, diagnosis and treatment of DLBCL
Shi, Y., Xu, Y. X., Shen, H., Jin, J., Tong, H., & Xie, W. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05880-z · Cited by 71
Khadka, R. H., Sakemura, R. L., Kenderian, S. S., & Johnson, A. J. (2019) · Immunotherapy · doi:10.2217/imt-2019-0074 · Cited by 66
Frigault, M. J., Nikiforow, S., Mansour, M. K., Hu, Z., Horowitz, M. M., Riches, M., Hematti, P., Turtle, C. J., Zhang, M., Perales, M., et al. (2020) · Blood · doi:10.1182/blood.2020006216 · Cited by 67
Neurotoxicity—CAR T-cell therapy: what the neurologist needs to know
Neill, L., Rees, J. H., & Roddie, C. (2020) · Practical Neurology · doi:10.1136/practneurol-2020-002550 · Cited by 67
Cao, Y., Xiao, Y., Wang, N., Wang, G., Huang, L., Hong, Z., Meng, L., Zhou, X., Wang, J., Yang, Y., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.08.012 · Cited by 64
Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Shin, E., Bak, S. H., Park, T., Kim, J.-W., Yoon, S. R., Jung, H., & Noh, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192907 · Cited by 71
A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy
Boulch, M., Cazaux, M., Cuffel, A., Ruggiu, M., Allain, V., Corre, B., Loe-Mie, Y., Hosten, B., Cisternino, S., Auvity, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101161 · Cited by 68
Hill, L. C., Rouce, R. H., Wu, M.-F., Wang, T., Ma, R., Zhang, H., Mehta, B., Lapteva, N., Mei, Z., Smith, T. S., et al. (2023) · Blood · doi:10.1182/blood.2023022204 · Cited by 65
Mohty, M., Gauthier, J., Malard, F., Aljurf, M. D., Bazarbachi, A. A., Chabannon, C., Kharfan‐Dabaja, M. A., Savani, B. N., Huang, H., Kenderian, S. S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0615-5 · Cited by 65
CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
Harrer, D. C., Dörrie, J., & Schaft, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235942 · Cited by 63
Roex, G., Feys, T., Beguin, Y. P., Kerre, T. C. C., Poiré, X., Lewalle, P., Vandenberghe, P., Bron, D., & Anguille, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020194 · Cited by 65
Rochigneux, P., Chanez, B., de Rauglaudre, B., Mitry, E., Chabannon, C., & Gilabert, M. (2021) · Cancers · doi:10.3390/cancers13020271 · Cited by 68
Goto, S., Sakoda, Y., Adachi, K., Sekido, Y., Yano, S., Eto, M., & Tamada, K. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02853-3 · Cited by 64
Non-viral transfection technologies for next-generation therapeutic T cell engineering
Raes, L., Smedt, S. C. D., Raemdonck, K., & Braeckmans, K. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107760 · Cited by 67
Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages
Ebrahimiyan, H., Tamimi, A., Shokoohian, B., Minaei, N., Memarnejadian, A., Hossein‐Khannazer, N., Hassan, M., & Vosough, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108587 · Cited by 64
Yan, X., Chen, D., Wang, Y., Guo, Y., Tong, C., Wei, J., Zhang, Y., Wu, Z., & Han, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00915-1 · Cited by 65
Wagner, D. L., Koehl, U., Chmielewski, M. M., Scheid, C., & Stripecke, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865424 · Cited by 65
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
Apollonio, B., Spada, F., Petrov, N., Cozzetto, D., Papazoglou, D., Jarvis, P., Kannambath, S., Terranova-Barberio, M., Amini, R., Enblad, G., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166070 · Cited by 64
PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
Unterrainer, M., Ruzicka, M., Fabritius, M. P., Mittlmeier, L. M., Winkelmann, M., Rübenthaler, J., Brendel, M., Subklewe, M. S., von Bergwelt‐Baildon, M., Ricke, J., et al. (2020) · European Radiology Experimental · doi:10.1186/s41747-020-00190-1 · Cited by 65
Strati, P., Nastoupil, L. J., Fayad, L., Samaniego, F., Adkins, S., & Neelapu, S. S. (2019) · Blood · doi:10.1182/blood.2019000888 · Cited by 63
McMillan, A., Phillips, E. H., Kirkwood, A. A., Barrans, S., Burton, C. H., Rule, S. A., Patmore, R. D., Pettengell, R., Ardeshna, K. M., Lawrie, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.016 · Cited by 63
G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma
Galli, E., Allain, V., Blasi, R. D., Bernard, S., Vercellino, L., Morin, F., Moatti, H., Caillat‐Zucman, S., Chevret, S., & Thiéblemont, C. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01006-x · Cited by 63
Hou, J., Ye, J. C., Pu, J. J., Liu, H., Ding, W., Zheng, H., & Liu, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01077-3 · Cited by 64
Defining and treating high-grade B-cell lymphoma, NOS
Olszewski, A. J., Kurt, H., & Evens, A. M. (2021) · Blood · doi:10.1182/blood.2020008374 · Cited by 63
Current landscape of clinical development and approval of advanced therapies
Iglesias-López, C., Agustí, A., Vallano, A., & Obach, M. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.11.003 · Cited by 67
Idecabtagene Vicleucel (ide-cel) CAR T-cell Therapy for Relapsed and Refractory Multiple Myeloma
Anderson, L. D. (2021) · Future Oncology · doi:10.2217/fon-2021-1090 · Cited by 68
Saifi, O., Breen, W. G., Lester, S. C., Rule, W. G., Stish, B. J., Rosenthal, A. C., Munoz, J. L., Herchko, S. M., Murthy, H. S., Lin, Y., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.11.031 · Cited by 63
Li, L., Li, Q., Yan, Z., Sheng, L., Fu, D., Xu, P., Wang, L., & Zhao, W. (2022) · Scientific Reports · doi:10.1038/s41598-022-16616-2 · Cited by 67
Li, W., Zhang, B., Cao, W., Zhang, W., Li, T., Liu, L., Xu, L., Gao, F., Wang, Y., Wang, F., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00402-5 · Cited by 66
Rejeski, K., Perez, A. P., Iacoboni, G., Blumenberg, V., Bücklein, V., Völkl, S., Penack, O., Albanyan, O., Stock, S., Müller, F., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg3919 · Cited by 64
CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis
Acharya, S., Başar, R., Daher, M., Rafei, H., Li, P., Uprety, N., Ensley, E. L., Shanley, M., Kumar, B., Banerjee, P. P., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0096 · Cited by 69
Brody, J., Jørgensen, J. M., Belada, D., Costello, R. T., Trněný, M., Vitolo, U., Lewis, D. J., Karimi, Y. H., Sureda, A. M., André, M. P. E., et al. (2025) · Blood · doi:10.1182/blood.2024026830 · Cited by 63
CAR T-cell immunotherapy of B-cell malignancy: the story so far
Halim, L., & Maher, J. F. (2020) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135520927164 · Cited by 65
Iancu, E. M., & Kandalaft, L. E. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.05.005 · Cited by 63
Kittai, A. S., Huang, Y., Gordon, M. J., Denlinger, N., Mian, A., Fitzgerald, L. A., Bishop, J., Nagle, S. J., Stephens, D. M., Jaglowski, S. M., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.09.028 · Cited by 62
Self-citationNagle, S. J., Murphree, C. R., Raess, P. W., Schachter, L. G., Chen, A., Hayes‐Lattin, B., Nemecek, E. R., & Maziarz, R. T. (2021) · American Journal of Hematology · doi:10.1002/ajh.26113 · Cited by 62
Self-citationBalancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
Geethakumari, P. R., Ramasamy, D. P., Dholaria, B., Berdeja, J. G., & Kansagra, A. J. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00635-3 · Cited by 67
Brammer, J. E., Braunstein, Z., Katapadi, A., Porter, K. M., Biersmith, M. A., Guha, A., Vasu, S., Yildiz, V. O., Smith, S. A., Buck, B. H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002303 · Cited by 62
Self-citationCohen, D., Luttwak, E., Beyar‐Katz, O., Krauthammer, S. H., On, Y. B., Amit, O., Gold, R., Perry, C., Avivi, I. M., Ram, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05551-5 · Cited by 62
Velasco, R., Mussetti, A., Villagrán‐García, M., & Sureda, A. M. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1144414 · Cited by 67
GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes
Uenishi, G. I., Repic, M., Yam, J. Y., Landuyt, A. E., Lakshmi, P. S., Guo, T., Zarin, P., Sassone‐Corsi, M., Chicoine, A. T., Kellogg, H., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.171844 · Cited by 62
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 78
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Köksal, H., Dillard, P., Josefsson, S. E., Maggadottir, S. M., Pollmann, S., Fåne, A., Blaker, Y. N., Beiske, K., Huse, K., Kolstad, A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018029678 · Cited by 67
Self-citationA brief history of CAR-T cells: from laboratory to the bedside
Styczyński, J. (2020) · Acta Haematologica Polonica · doi:10.2478/ahp-2020-0002 · Cited by 68
McNerney, K. O., DiNofia, A. M., Teachey, D. T., Grupp, S. A., & Maude, S. L. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0203 · Cited by 71
Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities
Kansagra, A. J., Farnia, S. H., & Majhail, N. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279151 · Cited by 62
Oluwole, O. O., Jansen, J. P., Lin, V. W., Chan, K., Keeping, S., Navale, L., & Locke, F. L. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.06.008 · Cited by 61
Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma
Andrews, D. W., Judy, K. D., Scott, C., Garcia, S. A., Harshyne, L. A., Kenyon, L. C., Talekar, K. S., Flanders, A. E., Atsina, K., Kim, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3805 · Cited by 62
Ho, J., Wang, L., Liu, Y., Ba, M., Yang, J., Zhang, X., Chen, D., Lu, P., & Li, J. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.007 · Cited by 61
The current landscape of immunotherapy for pediatric brain tumors
Hwang, E. I., Sayour, E. J., Flores, C., Grant, G. A., Wechsler‐Reya, R. J., Hoang-Minh, L., Kieran, M. W., Salcido, J., Prins, R. M., Figg, J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-021-00319-0 · Cited by 65
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
Wachsmann, T. L. A., Wouters, A. K., Remst, D. F. G., Hagedoorn, R. S., Meeuwsen, M. H., van Diest, E., Leusen, J. H. W., Kuball, J. H. E., Falkenburg, J. H. F., & Heemskerk, M. H. M. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2033528 · Cited by 66
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
Roex, G., Campillo-Davó, D., Flumens, D., Shaw, P. A. G., Krekelbergh, L., Reu, H. D., Berneman, Z. N., Lion, E., & Anguille, S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03326-6 · Cited by 62
Jin, C., Ma, J., Ramachandran, M., Yu, D., & Essand, M. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00875-5 · Cited by 62
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Donnadieu, E., Luu, M., Alb, M., Anliker, B., Arcangeli, S., Bonini, C., Angelis, B. D., Choudhary, R., Espie, D., Galy, A. H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003486 · Cited by 66
Barata, A., Hoogland, A. I., Kommalapati, A., Logue, J., Welniak, T. L., Hyland, K. A., Eisel, S. L., Small, B. J., Jayani, R., Booth‐Jones, M., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.05.015 · Cited by 61
Bove, C., Arcangeli, S., Falcone, L., Camisa, B., Khoury, R. E., Greco, B. M., Lucia, A. D., Bergamini, A., Bondanza, A., Ciceri, F., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005878 · Cited by 64
Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan
Jo, T., Yoshihara, S., Okuyama, Y., Fujii, K., Henzan, T., Kahata, K., Yamazaki, R., Takeda, W., Umezawa, Y., Fukushima, K., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18831 · Cited by 64
Duell, J., Leipold, A. M., Appenzeller, S., Fuhr, V., Rauert‐Wunderlich, H., Vià, M. D., Dietrich, O., Toussaint, C., Imdahl, F., Eisele, F., et al. (2023) · Blood · doi:10.1182/blood.2023021672 · Cited by 70
Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?
Mathias-Machado, M. C., de Jesus, V. H. F., Jacome, A. A. D. A., Donadio, M. D. S., Aruquipa, M. P. S., de Farias, J. P. F., Cunha, R., Silva, L. M. D., & Peixoto, R. D. (2024) · Cancers · doi:10.3390/cancers16030679 · Cited by 70
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects
Wang, Y., Buck, A., Piel, B. P., Zerefa, L., Murugan, N., Coherd, C. D., Miklosi, A. G., Johal, H., Bastos, R. N., Huang, K., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01952-w · Cited by 69
Novel strategies to manage CAR-T cell toxicity
Mulvey, A., Trueb, L., Coukos, G., & Arber, C. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01100-5 · Cited by 69
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
Raj, S. S., Fei, T., Fried, S., Ip, A., Fein, J. A., Leslie, L. A., Tomás, A. A., Leithner, D., Peled, J. U., Corona, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03532-x · Cited by 71
Self-citationStein-Merlob, A. F., Rothberg, M. V., Holman, P., & Yang, E. H. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01440-3 · Cited by 60
CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions
Gill, S. I., & Brudno, J. N. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320085 · Cited by 63
Leotta, S., Condorelli, A., Sciortino, R., Milone, G. A., Bellofiore, C., Garibaldi, B., Schininà, G., Spadaro, A., Cupri, A., & Milone, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11010253 · Cited by 64
Peinelt, A., Bremm, M., Kreyenberg, H., Cappel, C., Banisharif-Dehkordi, J., Erben, S., Rettinger, E., Jarisch, A., Meisel, R., Schlegel, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830773 · Cited by 62
CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
Todorović, Ž., Todorovic, D., Marković, V., Ladjevac, N., Zdravković, N., Djurdjevic, P. M., Arsenijević, N., Milovanović, M., Arsenijević, A., & Milovanović, J. (2022) · Current Oncology · doi:10.3390/curroncol29050293 · Cited by 62
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Hughes, A. D., Teachey, D. T., & Diorio, C. J. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01013-w · Cited by 69
“The JULIET trial investigating tisa-cel for LBCL had lower rates of ICANS with 26% of patients having any grade of ICANS and 58% of those being severe [11, 12].”
BackgroundMethodChimeric antigen receptor T‐cell therapies: Optimising the dose
Dasyam, N., George, P., & Weinkove, R. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14281 · Cited by 58
Maloney, D. G., Kuruvilla, J. G., Liu, F., Kostić, A., Kim, Y., Bonner, A., Zhang, Y., Fox, C. P., & Cartron, G. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01144-9 · Cited by 59
Next-generation cell therapies: the emerging role of CAR-NK cells
Başar, R., Daher, M., & Rezvani, K. (2020) · Hematology · doi:10.1182/hematology.2020002547 · Cited by 57
Fusaroli, M., Isgrò, V., Cutroneo, P. M., Ferrajolo, C., Cirillo, V., Bufalo, F. D., Raschi, E., Poluzzi, E., & Trifirò, G. (2022) · Drug Safety · doi:10.1007/s40264-022-01194-z · Cited by 59
Cheng, E. L., Cardle, I. I., Kacherovsky, N. A., Bansia, H., Wang, T., Zhou, Y., Raman, J., Yen, A., Gutierrez, D., Salipante, S. J., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c05349 · Cited by 60
Epperla, N., Feng, L., Shah, N. N., Fitzgerald, L. A., Shah, H., Stephens, D. M., Lee, C. J., Ollila, T. A., Shouse, G., Danilov, A. V., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01508-3 · Cited by 59
Engineering strategies to safely drive CAR T-cells into the future
Rossi, M., & Breman, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1411393 · Cited by 68
Song, M.-K., Park, B.-B., & Uhm, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205010 · Cited by 62
Lin, R. J., Lobaugh, S. M., Pennisi, M., Chan, H. T., Batlevi, Y., Ruiz, J. D., Elko, T. A., Maloy, M., Batlevi, C. L., Dahi, P. B., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.243246 · Cited by 59
Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease
Shrestha, B., Walton, K., Reff, J., Sagatys, E. M., Tu, N., Boucher, J. C., Li, G., Ghafoor, T., Felices, M., Miller, J. S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135754 · Cited by 58
Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies
Chakraborty, R., Hill, B. T., Majeed, A., & Majhail, N. S. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2020.10.002 · Cited by 58
Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy
Khelil, M. B., Godet, Y., Abdeljaoued, S., Borg, C., Adotévi, O., & Loyon, R. (2022) · Cancers · doi:10.3390/cancers14010260 · Cited by 63
Emerging CAR T Cell Strategies for the Treatment of AML
Vishwasrao, P., Li, G., Boucher, J. C., Smith, D. L., & Hui, S. K. (2022) · Cancers · doi:10.3390/cancers14051241 · Cited by 61
Optimizing the manufacturing and antitumour response of CAR T therapy
Liu, Y., Sperling, A. S., Smith, E. L., & Mooney, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00031-x · Cited by 60
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Zhang, Y., Zhou, W., Yang, J., Yang, J., & Wang, W. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00431-0 · Cited by 58
Kampouri, E., Ibrahimi, S. S., Xie, H., Wong, E. R., Hecht, J., Sekhon, M. K., Vo, A., Stevens‐Ayers, T., Green, D. J., Gauthier, J., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad708 · Cited by 63
Adaptive immune receptor repertoire analysis
Mhanna, V., Bashour, H., Quý, K. L., Barennes, P., Rawat, P., Greiff, V., & Mariotti‐Ferrandiz, E. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00284-1 · Cited by 66
Huang, Y., Shao, M., Teng, X., Si, X., Wu, L., Jiang, P., Liu, L., Cai, B., Wang, X., Han, Y., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101400 · Cited by 63
Fueling CARs: metabolic strategies to enhance CAR T-cell therapy
der Vreken, A. V., Vanderkerken, K., Bruyne, E. D., Veirman, K. D., Breckpot, K., & Menu, E. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00535-1 · Cited by 61
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities
Schroeder, T., Martens, T., Fransecky, L. R., Valerius, T., Schub, N., Pott, C., Baldus, C. D., & Stölzel, F. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07576-4 · Cited by 58
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
Kim, W. S., Kim, T. M., Cho, S., Jarque, I., Iskierka‐Jazdzewska, E., Poon, L. M., Prince, H. M., Zhang, H., Cao, J., Zhang, M., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00921-6 · Cited by 58
Cardiotoxicity of Contemporary Anticancer Immunotherapy
Dalbo, N., Patel, R. P., Parikh, R. B., Shah, S. P., Guha, A., Dani, S. S., & Ganatra, S. (2020) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00867-1 · Cited by 60
Liu, Y., Deng, B., Hu, B., Zhang, W., Zhu, Q., Liu, Y., Wang, S., Zhang, P., Yang, Y., Yang, J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004557 · Cited by 57
Mustafayev, K., & Torres, H. A. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.02.042 · Cited by 57
Metadata
- Authors
- Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., Awasthi, R., Chu, J., Anak, Ö., Salles, G., & Maziarz, R. T.
- Affiliations
- The University of Sydney (AU)
- From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago Medicine, Chicago (M.R.B.); Peter MacCallum Cancer Centre, St. Vincent’s Hospital and University of Melbourne, Melbourne, VIC (C.S.T.), and the Royal Prince Alfred Hospital and Department of Medicine, University of Sydney, Sydney (P.J.H.) — both in Australia; Winship Cancer Institute of Emory University, Bone Marrow and Stem Cell...
- Oslo University Hospital (NO)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 45-56
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903062212
- Cited by
- 4,112
- References
- 29
- Citations by year
- 2026: 363 · 2025: 507 · 2024: 593 · 2023: 593 · 2022: 693 · 2021: 624 · 2020: 502 · 2019: 218
- FWCI
- 125.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CAR T-cell therapy, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, CD19, autologous stem cell transplantation, cytokine release syndrome, neurological adverse events, relapse-free survival, complete response, immune checkpoint molecules
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Adult, Aged, Female, Humans, Male, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Survival Analysis, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
